A scholarly position

The case for nephro-obesity medicine as a discipline within nephrology.

Written for colleagues in nephrology and endocrinology. The claim is specific: the care of obesity in kidney disease has become coherent, distinct, and consequential enough to warrant a defined clinical and scholarly home — for kidney patients, one anchored in nephrology, with formal obesity-medicine competency and close endocrinology / CKM collaboration built in.

Nephro-obesity medicine is not currently an accredited board subspecialty, and this page does not claim otherwise. The claim is more modest and practical: care at the intersection of obesity and kidney disease now requires a coherent skill set that is not consistently trained to depth in nephrology, endocrinology, or obesity medicine alone. For kidney patients, that skill set should be anchored in nephrology — because the defining endpoints are renal — and built in collaboration with the other fields. What follows is the case, in six steps, and the honest limits of it.

Premise 1 · EpidemiologyTwo intersecting epidemics with a shared trajectory

Obesity is an independent, graded risk factor for incident chronic kidney disease and one of its fastest-growing drivers. It accelerates progression, drives obesity-related glomerulopathy, and complicates both dialysis access and transplant candidacy. The link is increasingly supported as causal by Mendelian-randomization studies of higher BMI and kidney endpoints, alongside large cohort data, and the population carrying both is large and growing.

Crucially, obesity is not a topic sitting beside nephrology; it pervades every one of its subdomains — glomerular disease, haemodialysis, peritoneal dialysis, transplantation, stones, electrolyte and acid–base disorders, AKI and CKD. A driver that touches every part of a specialty, and changes its endpoints, is the kind of thing specialties usually organise expertise around.

Premise 2 · MechanismA distinct pathophysiology, not a comorbidity

Obesity injures the kidney through mechanisms that are specific and increasingly well characterised: adaptive hyperfiltration and glomerulomegaly, RAAS and sympathetic activation, lipotoxicity and ectopic renal-sinus fat, adipokine signalling, and the metabolic milieu of insulin resistance. Obesity-related glomerulopathy is a nameable lesion with its own histology, distinguishable from diabetic nephropathy and from primary FSGS. A condition with its own mechanism and its own pathology deserves to be engaged in its own right, not treated only as background to other diagnoses.

A field earns a name when it has a mechanism of its own, a diagnostic problem of its own, and a therapeutics of its own. Nephro-obesity now has all three.

Premise 3 · TherapeuticsAn inflection point that lands between two specialties

The decisive change is pharmacological. Within a few years, GLP-1 receptor agonists (FLOW), SGLT2 inhibitors, and non-steroidal mineralocorticoid-receptor antagonists (FIDELIO-DKD, FIGARO-DKD) moved from glucose- or pressure-lowering agents to demonstrated renoprotective therapies, and dual and triple incretin agonists are advancing behind them. This creates a four-pillar strategy of cardio-reno-metabolic protection that must be sequenced and monitored in the specific setting of a failing nephron.

And this is precisely where existing training divides. The pharmacology of these agents is owned by endocrinology and obesity medicine. The failing nephron — GFR estimation across extremes of muscle mass, dose de-indexing, volume and electrolyte management, the histology, dialysis and transplant — is owned by nephrology. Using these drugs safely in the patient whose kidneys are failing belongs fully to neither. It requires both at once.

Premise 4 · The training gapNeither fellowship trains this well

General nephrology fellowship trains glomerular disease, dialysis, and transplantation in depth, but treats obesity largely as a background comorbidity to be referred out. Endocrinology and obesity-medicine training own incretin pharmacology and metabolic disease, but rarely engage the failing nephron, renal drug dosing, or the protein dilemma of weight loss in advanced CKD. The result is a reproducible gap — renal-safety surveillance during rapid pharmacological weight loss, dose adjustment in reduced GFR, nutritional reconciliation of fat loss against muscle, and perioperative management of the CKD patient going to metabolic surgery or onto a transplant list. These are common cases, today inconsistently owned.

Premise 5 · Why nephrology, specificallyThe organizing home is the nephron

If the discipline needs a home, the argument for nephrology is straightforward. The endpoints that define it are renal: albuminuria, GFR trajectory, progression to kidney failure, the biopsy, the dialysis and transplant continuum. The safety questions that make the therapeutics hard are renal. The pathology that names the field is renal. Obesity medicine is an essential complementary competency — and a formal one, through certification such as ABOM — but it is a competency the nephrologist adds, not the organizing framework of the discipline.

There is a clean precedent. Nephrology already subspecialises along exactly this kind of intersection: onco-nephrology, cardio-nephrology, interventional nephrology, glomerular disease. Cardio-nephrology is the closest analogy — it emerged when a neighbouring organ system therapeutics began to change renal endpoints, and nephrology organised a focused expertise around the overlap. Nephro-obesity is the same move one node over, and the CKM framework validates it institutionally.

Premise 6 · Institutional convergenceThe frameworks are already assembling

This is not a case argued from first principles alone; the major societies are already converging on it. The AHA introduced the cardiovascular-kidney-metabolic (CKM) syndrome framework in a 2023 Presidential Advisory, with staging spanning stages 0 through 4, and the first multisociety clinical practice guideline followed in 2026 — authored jointly by the AHA and ACC and co-endorsed by the ADA and the ASN. KDIGO convened a Controversies Conference on obesity and CKD (Prague, 2024), and the ASN issued its first Kidney Health Guidance on the management of obesity in kidney disease (2024). The intellectual architecture is being built in public, by the field own governing bodies. What is missing is the trained clinician who operates at its centre.

The strongest objection, met directly

The obvious counter is that endocrinology and obesity medicine have the more legitimate claim, because they own the therapeutics that made this field urgent. That claim is real and should be conceded plainly. But the question is not who owns the drug — it is who owns the endpoint. Albuminuria, GFR trajectory, progression to kidney failure, the biopsy, and the dialysis and transplant continuum are the outcomes that define success and the surfaces on which these drugs turn dangerous. Where the defining endpoints and safety questions are renal, the organizing home is nephrology — with obesity-medicine expertise built in as a required, formal competency.

The honest limits of the claim

Two caveats keep this argument credible. First, nephro-obesity medicine is at present an emerging clinical focus, not an accredited board subspecialty; this page argues for its recognition, it does not assert it. Second, parts of the evidence base are still maturing — several renal endpoints for dual and triple agonists have not yet been reported, and some agents remain investigational. A discipline should be honest about the front edge of its own evidence.

Taken together, the six premises make a modest and specific claim: a coherent body of knowledge exists, it is distinct from what adjacent fellowships train, its therapeutics are consequential and moving quickly, and — because its defining endpoints, safety questions, and pathology are renal — it is best anchored in nephrology, with obesity-medicine and endocrinology competency built in. Recognising it as a defined advanced focus would not create the need; the need already exists.

The Nephrobesity framework set out here — its domains, evidence base, and this case for the discipline — is developed and maintained by Amir Naderi, MD.

Read the substance behind the argument.

The ten clinical domains set out the knowledge base in full; the study library binds each claim to a primary source.

The ten clinical domains → Study library →

Evidence anchors

Ndumele CE, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023.
2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome.
KDIGO Controversies Conference: obesity and CKD — pathophysiology, prognosis, and management. Prague, 2024; conclusions in Kidney International, 2025.
ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases. J Am Soc Nephrol. 2024;35(11):1574–1588.
Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391:109–121.
Finerenone in diabetic kidney disease: FIDELIO-DKD and FIGARO-DKD (FIDELITY pooled analysis). Eur Heart J. 2022.

⚠︎Educational only. This page presents a scholarly position for professional discussion; it is not individual medical advice. Nephro-obesity medicine is an emerging clinical focus, not an accredited board subspecialty. Citations are evidence anchors; verify current data before formal use.